ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2010
Translating Sleeping Beauty transposition into cellular therapies: victories and challenges.
Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma.Gene therapy · 2021Trial
- Effect of degeneration stage on non-viral tissue transfection ofMolecular therapy. Nucleic acids · 2025Article
- Review
- Construction of a Set of Novel Transposon Vectors for Efficient Silencing of Protein and lncRNA Genes via CRISPR Interference.Molecular biotechnology · 2023Article
- Article
- Challenges and new technologies in adoptive cell therapy.Journal of hematology & oncology · 2023Review
- Enhanced Biosafety of theBiomolecules · 2023Article
- Early Subcellular Hepatocellular Alterations in Mice Post Hydrodynamic Transfection: An Explorative Study.Cancers · 2023Article
- Molecular and Functional Characterization of BDNF-Overexpressing Human Retinal Pigment Epithelial Cells Established byInternational journal of molecular sciences · 2022Article
- Advances and challenges of CAR T therapy and suitability of animal models (Review).Molecular and clinical oncology · 2022Review
- Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.Frontiers in bioengineering and biotechnology · 2022Review
- The Past, Present, and Future of Non-Viral CAR T Cells.Frontiers in immunology · 2022Review
- A Novel off-the-Shelf Trastuzumab-Armed NK Cell Therapy (ACE1702) Using Antibody-Cell-Conjugation Technology.Cancers · 2021Article
- Immune cell labelling and tracking: implications for adoptive cell transfer therapies.EJNMMI radiopharmacy and chemistry · 2021Review
- CAR T-Cell Production Using Nonviral Approaches.Journal of immunology research · 2021Review
- Review
- Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield.Cancers · 2020Review
- Rigidity and flexibility characteristics of DD[E/D]-transposases Mos1 and Sleeping Beauty.Proteins · 2019Article
- Evolution-guided evaluation of the inverted terminal repeats of the synthetic transposon Sleeping Beauty.Scientific reports · 2019Article
- CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.Frontiers in immunology · 2019Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Recent results confirm that long-term expression of therapeutic transgenes can be achieved by using a transposon-based system in primary stem cells and in vivo. Transposable elements are natural DNA transfer vehicles that are capable of efficient genomic insertion. The latest generation, Sleeping Beauty transposon-based hyperactive vector (SB100X), is able to address the basic problem of non-viral approaches - that is, low efficiency of stable gene transfer. The combination of transposon-based non-viral gene transfer with the latest improvements of non-viral delivery techniques could provide a long-term therapeutic effect without compromising biosafety. The new challenges of pre-clinical research will focus on further refinement of the technology in large animal models and improving the safety profile of SB vectors by target-selected transgene integration into genomic "safe harbors." The first clinical application of the SB system will help to validate the safety of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.